Xtent Aims For Long-Lesion Indication For Its Custom NX Drug-Eluting Stent
This article was originally published in The Gray Sheet
Executive Summary
Buoyed by recent European clinical trial results, drug-eluting stent developer Xtent expects to begin a U.S. pivotal trial later this year in support of an indication no other drug-eluting coronary stent company has: treatment of long lesions and multiple lesions